long intergenic non-protein coding RNA 2435Genealiases: []
Q-omics provides the consensus-scored LINC02435 profile across patient tissues and cancer cell-line models. LINC02435 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LINC02435 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, LINC02435 RNA expression shows 12,475 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LGG, LUSC, and ESCA as cancer lineages where LINC02435 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02435 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02435 survival associations across molecular data types. LINC02435 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02435 RNA expression–survival associations across cancer types. High LINC02435 expression shows unfavorable associations in LGG, GBM, ACC, KIRP and KIRC, but favorable associations in THYM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LINC02435 RNA expression.
This table summarizes LINC02435 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02435. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02435 shows lower tumor expression in LUSC, BRCA, KICH and LUAD and higher tumor expression in COAD and KIRP. The LUSC box plot shows higher LINC02435 RNA expression in normal versus tumor tissue (log2 FC = −0.455, t-test p < 0.001).
This table shows molecular features associated with LINC02435 in patient tissues and cancer cell lines. In patient samples, LINC02435 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
